CCNB2 and prostate carcinoma: Relying on the TIMER 2.0 database, we found that CCNB2 was overexpressed in most tumor tissues, such as bladder cancer (BLCA), breast cancer (BRCA), cervical cancer (CESC), esophageal cancer (ESCA), prostate cancer (PRAD) (p < 0.05), and clear cell renal cell carcinoma (ccRCC) (p < 0.001) (Fig. 2A).